SEATTLE, August 4, 2020 (GLOBE NEWSWIRE) – Adaptive Biotechnologies (Nasdaq: ADPT) today announced the launch of immunoSEQ® T-MAP ™ COVID, an exclusive product of studies and knowledge studies service that, as it should be and reproduceibly measures T- The immune reaction of cells to progressive vaccines and controls the patience of this reaction over time. This product is based on the knowledge of Snyder et al., Available today, which maps the T cells of more than 1000 patients with SARS-CoV-2-specific antigens that cause an immune reaction. This knowledge also demonstrates that SARS-CoV-2-specific T cells persist in patients recovered for more than 90 days, adding vital data to the ongoing effort to describe COVID-19 immunity. These effects are enhanced through ImmuneCODE, a revolutionary open knowledge base developed with your Microsoft spouse, to suppress the immune reaction of T cells to the COVID-19 virus at the point of population with the study community. A summary detailing the underlying method of ImmuneCODE, which adds the latest edition of the knowledge base, should be obtained, and the manuscript is recently being revised for long-term publication.
immunoSEQ T-MAP COVID provides researchers with a quantitative map of T cell receptors (TCR) and SARS-CoV-2 antigens that stimulate immune reaction to vaccines and other treatments that come for COVID-19. This high-resolution, high-resolution, high-resolution, reproducible molecular knowledge will be obtained through Adaptive’s existing cloud immunoSEQ analyzer to facilitate immune reaction research and visualization.
“ImmuneCODE’s knowledge and analysis to date have several real-world programs to deal with the COVID-19 pandemic, adding support for vaccine trials and the expansion of healing,” said Peter Lee, Microsoft’s corporate vice president of Research and Incubations. “As we continue to expand this innovative knowledge base and measure the patience of adaptive immune reaction over time, those critical findings will advance current and new efforts to help this global public aptitude crisis.”
The data from Snyder et al. determine the magnitude and dynamics of T cells’ reaction to SARS-CoV-2 infection in more than 1,000 patients and several thousand controls. First, Adaptive’s immune medicine platform is used to identify portions of the virus that induce a T-cell reaction. This knowledge verifies the effects of other studies that seem to indicate that the T-cells’ reaction to SARS-CoV-2 is directed as opposed to a small amount of viral antigens in addition to the complex protein, the existing target for maximum vaccination. These goals may indicate the design or improvement of next-generation vaccines.
Then, the shared “public” T-cell receptors that are specific to those immunogenic parts of the virus were identified. These TCRs enable T-cell response to the virus to be measured and tracked over time at the individual and population levels. Most notably, >90% of patients still have these shared SARS-CoV-2 specific T cells for several months post confirmed diagnosis, the maximum time period currently available to assess response. Previously published research on other coronavirus infections have demonstrated persistent T cells for years following initial infection, even when antibodies are undetectable in convalescent patients, highlighting the importance of the T-cell response in understanding immunity to the virus.
Snyder and cabbage. may be in: https://www.medrxiv.org/content/10.1101/2020.07.31.20165647v1
About T Cells T cells are the first to respond to the adaptive immune formula to trip over any virus. They multiply rapidly and circulate in the blood to attack the virus, before symptoms appear. Among many other jobs, T cells also recruit B cells to produce antibodies after about a week or two to provide immunity to long-term infections. T cells involve a large amount of data that can provide a constant and traceable measure of the immune reaction to COVID-19 from initial exposure to viral clearance.
T cells can “remember” beyond infections and kill pathogens if they reappear. Since many researchers have reported decreasing antibody signals against SARS-CoV-2 over time, T cells want to be studied to assess the length of time patients remain resistant to reinfection. Because T cells circulate freely in the blood, they are a simple and desirable goal for evaluating SARS-CoV-2 exposure and possible immunity.
About ImmuneCODE ImmuneCODE is an open knowledge base that provides a detailed population-level view of the adaptive immune reaction to the COVID-19 virus. Adaptive Biotechnologies and Microsoft make this knowledge lost to any researcher, public official, or organization around the world to drive responses to the global pandemic. The knowledge base comprises detailed data on the virus’s express T cells, as well as virus-related antigens that they recognize. T-cell reactions to these antigens will be monitored across the population to create an immune reaction with thousands of anonymous samples combined from organizations around the world and ImmuneRACE, the virtual clinical examination presented in May to help locate a solution for COVID-19.
* Providence, a large health system with 51 hospitals, including the one near Seattle that treated the first U.S. COVID-19 patient, is an initial clinical collaborator. A sampling of some of our other participating institutions include Institute for Systems Biology (ISB), BloodWorks Northwest, Hospital 12 de Octubre, i+12/CNIO (Madrid, Spain), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS (Meldola, FC – Italy) / AUSL-Romagna and Department of Experimental, Diagnostic and Specialty Medicine (DIMES), and Università di Bologna (Italy) and the NIH in partnership with ASST Spedali Civil di Brescia, Italy and the University of Milano Bicocca-Fondazione MBBM Ospedale San Gerardo, Monza, Itlay. This list is growing as we continue to work with other investigators globally to collect and sequence valuable patient cohorts. Institutions or collaborators interested in contributing blood samples can direct inquiries to [email protected].
About Adaptive Biotechnologies Adaptive Biotechnologies Adaptive Biotechnologies is an advertising biotechnology corporation that focuses on leveraging the inherent biology of the adaptive immune formula to reshape the diagnosis and remedy of the disease. We believe that the adaptive immune formula is nature’s best diagnosis and remedy for maximum diseases, however, the inability to decode it has prevented the medical network from making the most of its capabilities. Our patented immune medicine platform showcases and translates the great genetics of adaptive immune formula with scale, accuracy and speed to expand products in life science research, clinical diagnosis and drug discovery. We have two advertising products and a physically powerful clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune diseases and infectious diseases. Our purpose is to expand and market clinical immune products tailored to each patient. For more information, stop at adaptivebiotech.com and stay in touch with us at www.twitter.com/adaptivebiotech.
Forward Looking StatementsThis press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available to Adaptive. All statements contained in the press release other than statements of historical fact are forward-looking statements, including statements regarding the ability to map adaptive immune responses to COVID-19, the ability to successfully collect a sufficient number and quality of samples through ImmuneRACE, the ability to efficiently and effectively process data with ImmuneCODE, to leverage any findings or data to advance solutions to diagnose, treat and prevent COVID-19, the ability to develop, commercialize and achieve market acceptance of the Adaptive’s TCR-Antigen Map and other current and planned products and services, research and development efforts. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, which are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents Adaptive files with the Securities and Exchange Commission from time to time.
For information: Beth Keshishian, Adaptive Media (917) 912-7195 [email protected]